Entero Healthcare Solutions Limited has announced that its officials will be holding a group meeting with analysts and institutional investors on July 15, 2025, in Mumbai. The interaction is scheduled to commence at 02:00 pm onwards and will focus on discussions based exclusively on publicly available information, ensuring no unpublished price-sensitive information (UPSI) is disclosed.
Analyst/Institutional Investor Meeting Details| Particulars | Details |
|---|
| Company | Entero Healthcare Solutions Limited |
| Date of Meeting | July 15, 2025 |
| Time | 02:00 pm onwards |
| Type of Interaction | Group Meeting |
| Location | Mumbai |
| Information Basis | Publicly available information |
| UPSI Disclosure | None intended |
Meeting Details and Regulatory Compliance
The upcoming meeting is being conducted in compliance with Regulation 30(6) read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed entities to disclose the schedule of analyst or institutional investor meetings to the stock exchanges, promoting transparency and ensuring that all market participants have access to information regarding such interactions. The company has explicitly stated that the discussions during the group meeting will be based solely on information that is already in the public domain. This is a critical aspect of regulatory compliance, as it prevents the selective disclosure of material information that could potentially influence stock prices. The assurance that no unpublished price-sensitive information (UPSI) is intended to be discussed underscores the company's commitment to fair disclosure practices and maintaining an equitable information environment for all investors.
Purpose and Scope of Interaction
Analyst and institutional investor meetings serve as a vital platform for companies to engage with key stakeholders in the financial community. These interactions allow analysts to gain a deeper understanding of the company's business operations, strategic direction, and financial performance, based on previously disclosed information. For institutional investors, such meetings provide an opportunity to clarify doubts, seek additional context on public disclosures, and assess the management's perspective on various aspects of the business. While these meetings are crucial for fostering investor confidence and improving market understanding of the company, the strict adherence to discussing only publicly available information ensures that the playing field remains level for all investors, regardless of their participation in such specific interactions. This practice aligns with the broader objectives of SEBI's regulations, which aim to enhance corporate governance and protect investor interests by preventing insider trading and information asymmetry.
Company's Commitment to Transparency
Entero Healthcare Solutions Limited, through its Vice President-General Counsel, Company Secretary & Compliance Officer, Sanu Kapoor, has formally intimated the stock exchanges, BSE Limited and National Stock Exchange of India Limited, about this scheduled meeting. The intimation highlights the company's proactive approach to investor relations and its commitment to fulfilling regulatory obligations. The company has also included a standard disclaimer, noting that "changes may happen due to exigencies on the part of Participants / Company." This acknowledges the dynamic nature of corporate schedules and the potential for unforeseen circumstances to necessitate adjustments to the meeting plan. Such disclaimers are common practice and provide flexibility while maintaining transparency regarding potential alterations.
Market Context and Investor Relations
For a company listed on major Indian stock exchanges like BSE and NSE (Scrip Code BSE: 544122, NSE: ENTERO, ISIN: INE010601016), regular engagement with analysts and institutional investors is a cornerstone of robust investor relations. These interactions contribute to better analyst coverage, which in turn can lead to more informed investment decisions by the broader market. By providing a structured forum for dialogue, Entero Healthcare Solutions Limited aims to maintain open communication channels with the investment community. The company's registered office is located at Plot No. 1-35, Building - B, Industrial Area Phase I, 13/7 Mathura Road, Faridabad, Haryana - 121003, with its corporate office at Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Bandra (East), Mumbai - 400051. This formal communication from the company's compliance officer reinforces its adherence to corporate governance standards and its dedication to keeping the market well-informed about its investor engagement activities.
